LEPR Genotype

If you have ever wondered why two people can eat the same food, move the same amount, and end up at very different weights, part of the answer sits in the genes that govern hunger and fullness. LEPR (the leptin receptor gene) builds the docking station for leptin, the hormone fat cells use to tell your brain you have eaten enough. Variations in this gene can quietly shift that conversation.

This test reads your inherited sequence at LEPR. It looks for rare, severe variants that drive extreme childhood obesity and hormone problems, and for common variations that may nudge body weight, insulin sensitivity, blood pressure, and reproductive health in subtle ways. The result is a one-time read of an inherited tendency that standard cholesterol, glucose, or thyroid panels were never designed to detect.

What This Test Actually Reads

Your LEPR genotype is the sequence you inherited at the leptin receptor gene. Two copies of the gene come together (one from each parent), and the specific letters at certain spots determine how well the receptor works. The most studied common variant is called Q223R (also written as rs1137101), a single-letter change that swaps one building block of the receptor for another. Other common variants include K109R, K656N, and several tagging variants that mark different regions of the gene.

Rare LEPR variants are a different story. When both copies of LEPR carry a damaging change (biallelic loss-of-function), the receptor barely works at all. The result is a recessive condition called leptin receptor deficiency, which is estimated to affect roughly 1.34 per 1 million people in Europe. Whether a single damaging copy (heterozygous variant) on its own causes higher weight is still debated. Earlier reviews suggested it might, but a 2024 study of about 10,000 participants with confirmation in 200,000 UK Biobank individuals concluded that monoallelic pathogenic LEPR variants do not elevate the risk of obesity or BMI on their own.

Severe Inherited Forms: LEPR Deficiency

When both LEPR copies are damaged, the brain stops hearing the fullness signal. People with this form develop early-onset severe obesity, almost universal hyperphagia (extreme hunger that does not turn off), and frequent pituitary hormone deficits. A multicenter cohort study confirmed childhood-onset obesity in all confirmed LEPR-deficient patients, with frameshift and missense variants being the most common types found. These cases are rare but life-altering, and many experts believe they are underdiagnosed.

Confirming biallelic LEPR deficiency has direct treatment implications. Setmelanotide (brand name Imcivree) is FDA-approved for chronic weight management in people aged two years and older with obesity due to genetically confirmed LEPR deficiency. That makes a genetic diagnosis actionable rather than purely descriptive in this rare population.

Heterozygous (one-copy) LEPR variants are less clear. Older case-series and reviews described higher body weight and fat mass in some carriers, but a 2024 functional study by Delplanque and colleagues, which assessed heterozygous LEPR variants in about 10,000 participants and confirmed findings in 200,000 UK Biobank individuals, concluded that monoallelic pathogenic LEPR variants do not by themselves raise obesity risk or BMI. Among 55 heterozygotes previously reported in the literature, only about 27 percent had obesity. The current picture is that one damaged copy is, on average, not enough to drive higher weight.

Common LEPR Variants and Body Weight

For the common LEPR variants most people might carry, the picture is more nuanced. A large systematic review and meta-analysis of Q223R, K109R, and K656N found no overall association with being overweight when results were pooled. A separate meta-analysis of rs1137101 in Asian and Caucasian populations did find a significant association with obesity risk. The pattern that emerges is that single common variants rarely flip a switch on body weight by themselves, but they may shift the odds in specific contexts.

Context matters more than the variant alone. In the HERITAGE family study, Caucasian men carrying the R223 allele had higher BMI, body fat, and blood leptin than non-carriers. In a multi-ethnic Malaysian cohort, LEPR K109 and Q223 alleles were linked with higher blood pressure and adiposity measures, but the strongest pattern was structured by ethnicity, and LEP and LEPR variants showed combined effects on under-the-skin fat and leptin levels. In the CoLaus study, several LEPR variants showed sex-specific associations with overweight, waist circumference, and fat mass. In Spanish obese children, the variant rs11804091 was associated with BMI and, in girls specifically, with insulin resistance markers and adiponectin.

Why the Same Variant Can Look Different in Different People

It is easy to read a meta-analysis that finds no effect of Q223R on obesity and then read a population study that finds a clear effect in Caucasian men, and walk away confused. Both are correct. LEPR is not a yes-or-no switch for body weight. It is a small dial in a larger system that also includes sex, ethnicity, age, diet, activity, and other genes in the leptin-melanocortin pathway. A variant that does little against a background of low metabolic stress may matter when that same person gains weight or develops insulin resistance. Your genotype tells you which dial you started with, not what dial position will dominate your health in every situation.

Type 2 Diabetes and Insulin Resistance

The meta-analytic evidence here is mixed. One meta-analysis (Yang and Niu, 2018) found that the Q223R and K109R variants were not significantly associated with type 2 diabetes overall. Two other meta-analyses, however, reached the opposite conclusion: an earlier meta-analysis by Yang and colleagues (2016) found rs1137101 significantly associated with type 2 diabetes across multiple genetic models, and a more recent analysis by Veerabathiran and colleagues (2024) reported a similar significant link. Taken together, the safe reading is that LEPR variants are not a clear-cut diabetes risk gene on their own but may contribute in some populations.

Population studies illustrate where the signal tends to show up. In a Gujarati cohort, people carrying two copies of the G allele at rs1137101 (the GG genotype) had about 1.66 times the risk of type 2 diabetes compared with non-carriers, along with higher fasting glucose and cholesterol. In Saudi women, the same GG genotype was linked with higher BMI, leptin, insulin, HOMA-IR (a calculated marker of insulin resistance), and lower ghrelin. In an Indian pregnancy cohort, there was no overall LEPR effect on insulin resistance, but homozygous GG carriers within the pregnant group had higher HOMA-IR.

What this means for you is that LEPR is not a stand-alone diabetes risk gene. It may compound risk in people who already carry other metabolic stressors, and it can show up most clearly when your body is challenged by pregnancy, weight gain, or aging.

Reproductive Health and PCOS

LEPR variants have been tied to reproductive outcomes, especially in women with polycystic ovary syndrome (PCOS). In Iranian women with PCOS, the GG genotype at rs1137101 was significantly more common in the infertile subgroup. In a comparative study, LEPR variants rs1137100, rs1137101, and rs2025804 were associated with PCOS in Bahraini women but not in Tunisian women, again showing how ethnicity shapes the signal. If you have PCOS or unexplained fertility challenges, your LEPR genotype is one piece of background information that may help you understand your own pattern.

Blood Pressure

In a Korean study, a LEPR intronic Del/Ins variant carried a different signal: the insertion allele was associated with a lower risk of hypertension. Combined with a microRNA variant, the combination predicted hypertension risk in Koreans. A separate meta-analysis of the more widely studied Gln223Arg polymorphism, however, found no significant overall association with hypertension. The takeaway is that LEPR sits inside a broader signaling network that can tilt blood pressure regulation in either direction depending on the variant and population, and the evidence is far from uniform.

Cancer Associations

Cancer links are emerging but not strong enough to drive personal decisions alone. Certain LEPR tagging variants, including rs10493380, have been associated with pancreatic cancer risk in women, and polymorphisms in the LEP and LEPR genes have been associated with survival after colorectal cancer diagnosis in a Canadian cohort. A large pooled analysis of rs1137101 and overall cancer risk, on the other hand, did not find a significant association. These findings are useful context for someone who already has a family history of these cancers, not a stand-alone reason to act.

Selected LEPR Findings

Source: Bender et al. (CoLaus/systematic review); Chagnon et al. (HERITAGE Family Study); Parmar et al. (Gujarat cohort).

What this means for you: a single common LEPR variant rarely explains your weight, blood sugar, or blood pressure on its own. Your genotype is a starting point, useful when paired with ongoing tracking of weight, glucose, lipids, blood pressure, and family history.

When Results Can Be Misleading

• Variant panel coverage: the test only detects the specific LEPR variants it is designed to look for. A negative result does not rule out rare or undiscovered variants in the same gene that a broader sequencing test might find.
• Ethnic-specific allele frequencies: the clinical meaning of a LEPR variant depends on ancestry. Studies have found different effects across European, Asian, Middle Eastern, North African, and Sub-Saharan populations, and a result interpreted using one reference population may not directly transfer to another.
• Variants of uncertain meaning: because LEPR can carry rare changes whose clinical significance has not been pinned down, some results may be flagged as uncertain. A flagged variant does not automatically mean disease and may need expert review.
• Clinical-grade vs consumer testing: the same LEPR site read by a clinical lab and by a direct-to-consumer chip can sometimes give different calls, especially for rare variants. If a consumer test result drives an important decision, confirm with a clinical-grade assay.

Your Result Is a One-Time Read

Unlike cholesterol or blood sugar, your LEPR genotype does not change over your lifetime. You do not need to retest the gene itself unless the variant call confidence is in question (for example, if the result is unexpected and a different method is warranted to confirm it). The value of this test is not in repeating it. It is in feeding the result into your ongoing decisions for years to come, alongside companion tests that do shift over time.

Those companion phenotype tests matter more after you have your LEPR result. If you carry a variant associated with higher insulin resistance, glucose, HbA1c (a three-month blood sugar average), insulin, and HOMA-IR become more meaningful to track regularly. If a variant has been tied to blood pressure, regular home blood pressure readings and clinic measurements gain weight. The genotype is fixed; the phenotypes it influences are not.

What to Do With an Out-of-Pattern Result

If your test reveals a rare, damaging variant (especially in both copies of LEPR), the next step is referral to a genetic counselor and an endocrinologist with experience in monogenic obesity. These cases are rare enough that general primary care is often not the right setting. Confirmed biallelic LEPR deficiency also opens the door to a specific FDA-approved therapy, setmelanotide (Imcivree), which is indicated for chronic weight management in this group. You should also talk to biological family members, because both parents are carriers when a child has two damaged copies, and siblings have a known chance of being affected.

If your result shows a common variant associated with insulin resistance, weight gain, or PCOS in your ancestry group, the action is to tighten the cadence of phenotype monitoring. That typically means more frequent metabolic panels, lipid panels, and where relevant, hormone testing. Pair the result with a fasting insulin, HOMA-IR, and a hemoglobin A1c at baseline, then repeat them on a schedule that matches your other risk factors. If you also have PCOS, unexplained fertility issues, or a family history of severe early-onset obesity, this is the point to involve a specialist rather than wait for downstream lab numbers to drift.